ascendis pharma glp-1 receptor agonist weight management diabetes treatments Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug Evolution of GLP‐1 Receptor Agonists

Real-world evidence from observational studies consistently shows that GLP-1 RA use is associated with reduced risk of hepatic decompensation even in patients with established cirrhosis, supporting cautious use in this population

Powerful Probiotic Blend - Berberine makes it easier to maintain weight goals, Chicory (prebiotic fiber) promotes gut health, Probiotics balance belly bacteria, and Turmeric reduces discomfort via antioxidant benefits

Similar results were observed in the STEP-HFpEF DM trial

Who is considered higher risk

Obesity and HS are closely linked: the prevalence of obesity is higher in patients with HS, and conversely, obesity may predispose individuals to develop HS

Taken together, these findings demonstrate that gut microbiota and their metabolites exert dual and context-dependent effects on GLP-1 secretion and signaling